STOCKS TELEGRAPH

Tag: CPHI Stock

  • China Pharma Holdings Inc. (CPHI) Sees Weekend Surge in Apparent Pump and Dump

    China Pharma Holdings, Inc. (NASDAQ: CPHI) had a lackluster trading day last Friday, experiencing a 1.4% decline with minimal trading activity. However, as the closing bell rang, the after-hours session ushered in an unexpected turn of events. CPHI surged a remarkable 31%, accompanied by a surge in trading volume to 1.6 million shares, a stark contrast from the subdued activity earlier in the day.

    Market Reaction

    The sudden spike in CPHI’s stock price during after-hours trading caught many investors off guard, particularly given the absence of any apparent catalysts. This surge has left some market participants wary, speculating that a subsequent profit-taking dip may be looming on the horizon. Despite this uncertainty, bullish sentiment prevails, with investors eagerly riding the wave of momentum.

    China Pharma Holdings, Inc. is a pharmaceutical company engaged in the development, manufacturing, and marketing of a diverse range of products. Their product portfolio encompasses treatments for Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products.

    Breaking Down the Spike

    The company’s recent surge in stock price could be attributed to various factors, including speculation surrounding potential developments within its product pipeline or broader market trends. Additionally, the surge highlights the appeal of China-based stocks, particularly during extended trading hours, due to their historically lower trading volumes, which can facilitate significant price movements.

    China Pharma, operating through Helpson, currently operates two production facilities in Haikou, Hainan Province, PRC. These facilities adhere to stringent quality control measures in compliance with the PRC’s Good Manufacturing Practices (GMP) standards and relevant NMPA regulations, ensuring the consistency and quality of their products.

    Looking Ahead

    Looking ahead, the trajectory of CPHI’s stock price remains uncertain, with much hinging on continued trading volume. Despite the current bullish sentiment, investors are advised to exercise caution and closely monitor market developments.

    Overall, China Pharma Holdings, Inc.’s after-hours surge highlights the unpredictability of the stock market and the potential for significant price movements outside of regular trading hours. As investors brace for the week ahead, all eyes remain on CPHI’s trading activity and any forthcoming developments that may impact its stock price.

  • China Pharma Holdings, Inc. (CPHI) Stock Soaring in Premarket Despite no Reason

    China Pharma Holdings, Inc. (CPHI) Stock Soaring in Premarket Despite no Reason

    China Pharma Holdings, Inc. (CPHI) is a biopharmaceutical firm focused on the development, manufacturing, and marketing of products for treating cardiovascular, CNS, and digestive disorders. The products of the company include cerebroprotein hydrolysate for memory decline, gastrodin for loss of concentration, propyl gallate for cerebral thrombosis, bumetanide for edema, and candesartan for hypertension.

    The price of CPHI stock during the regular trading on February 3, 2022, was $0.49 with a 17.2% gain. At last check in the premarket on February 4, 2022, the stock further jumped by 10.1%.

    CPHI: Key Financials

    On November 12, 2021, CPHI released its financial results for the quarter ended September 30, 2021. Some of the key features are discussed below.

    Revenue

    Revenue recorded in Q3 2021 was $2.0 million compared to $2.4 million in the same period of 2020. A decline of 17.6% was observed in the revenue over the period of the year. The decline in the revenue was the result of the extension of the national centralized drug acquisitions scope and the associated price drop. The financial analysts also observed that the company missed the estimated revenue target by $307.2 thousand.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $0.8 million or $0.02 compared to $1.0 million or $0.02 in the same quarter of 2020. The net loss was reduced over the period of the year due to a reduction in selling costs in 2021. The company missed the estimated EPS by $0.04/

    CPHI: CEO Comments

    Speaking at the occasion, CPHI CEO Zhilin Li stated that the company focused on the consistency assessment of its registered products in the quarter. He further added that the company’s lead product Candesartan had passed the consistency assessment test. The company had submitted the application resources to the National Medical Products Administration.

    Conclusion

    CPHI stock is 45% down the past six months due to economic restraints caused as a result of the pandemic. The company’s stock is in a good position in the recent premarket due to uncertain factors as no official statement, SEC filing, or forthcoming event is listed on the company’s website.

  • CPHI Stock Announces Incredible Fiscal Year For 2020

    China Pharma Holdings, Inc. (CPHI) a New York stock exchange-listed pharmaceutical company that produces and advertises a diverse portfolio of products, focuses on diseases with high transmission rates and high mortality rates in China. The company’s efficient business model driven by market demand combined with a very large distribution network across all major cities in China is anticipated to generate massive revenue as the new GMP-certified products release. CPHI stock has also made a subsidiary company known as, Hainan Helpson Medical & Biotechnology Co., located in Haikou city, which specializes in medicine production.

    The company collected net revenue of $10.9M due to foreign trading of COVID-19 testers as market demand for covid related products increased and popped their gross margin from 13.6% in the fiscal year 2019 to 18% in the fiscal year 2020. A Net loss of $2.9 million took place in 2020 against a staggering $20.7 million loss in the fiscal year 2019.

    CPHI Business model variation 

    Ms. Zhilin Li, China Pharma’s Chairman, and CEO stated, “The outbreak of COVID-19 early in this year has created a substantial, negative impact on sales of pharmaceutical companies, including ours. Many people try to avoid going to hospitals for fear of cross-contamination or potential infection” However the company amended its business model to a more consumer-centric approach and started producing products related to Coronavirus which had huge market demand and surged their revenue substantially.

    However, due to unpredicted variation in product demand, market competitiveness; slow-progressing economy, and low levels of RnD, CPHI stock has accumulated a loss of a collective $23M in the past two years and has the company striving for better financial results.